Dec 16 (Reuters) - Amgen Inc -
* Top-line results from approximately 27,500-patient event-driven fourier study are anticipated in q1 of 2017
* Amgen Inc - "effect of repatha on cardiovascular morbidity and mortality has not yet been determined"
* CHMP of EMA has adopted positive opinion for extension to marketing authorization of new 420 mg single-dose delivery option for repatha
* Repatha amd will be available in europe during 2017 depending on reimbursement requirements Source text for Eikon: Further company coverage: